| 產(chǎn)品編號(hào) | bs-7902R-PE-Cy5.5 |
| 英文名稱(chēng) | Rabbit Anti-phospho-FRS2(Tyr436)/PE-Cy5.5 Conjugated antibody |
| 中文名稱(chēng) | PE-Cy5.5標(biāo)記的磷酸化成纖維細(xì)胞生長(zhǎng)因子受體底物2抗體 |
| 別 名 | p-FRS2(Tyr436); phospho-FRS2(Y436); FRS2(phospho-Y436); FRS2(phospho-Tyr436); p-FRS2(Y436); FGFR signaling adaptor SNT; FGFR signalling adaptor; FGFR substrate 2; FGFR-signaling adaptor SNT; Fibroblast Growth Factor Receptor Substrate 2; FRS 2; FRS2_HUMAN; FRS2A; FRS2alpha; SNT 1; SNT; SNT-1; SNT1; Suc 1 Associated Neurotrophic Factor Target; Suc1 associated neurotrophic factor target 1; Suc1-associated neurotrophic factor target 1. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 產(chǎn)品類(lèi)型 | 磷酸化抗體 |
| 研究領(lǐng)域 | 細(xì)胞生物 信號(hào)轉(zhuǎn)導(dǎo) 生長(zhǎng)因子和激素 激酶和磷酸酶 細(xì)胞膜受體 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Rat, (predicted: Human, Mouse, Dog, Pig, Cow, Horse, Rabbit, ) |
| 產(chǎn)品應(yīng)用 | IF=1:50-200
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 57kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthesised phosphopeptide derived from human FRS2 around the phosphorylation site of Tyr436 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: Adapter protein that links FGR and NGF receptors to downstream signaling pathways. Involved in the activation of MAP kinases. Modulates signaling via SHC1 by competing for a common binding site on NTRK1. Tissue specificity:Highly expressed in heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis. Function: Adapter protein that links activated FGR and NGF receptors to downstream signaling pathways. Plays an important role in the activation of MAP kinases and in the phosphorylation of PIK3R1, the regulatory subunit of phosphatidylinositol 3-kinase, in response to ligand-mediated activation of FGFR1. Modulates signaling via SHC1 by competing for a common binding site on NTRK1. Subunit: Part of a complex containing FRS2, GRB2, GAB1, PIK3R1 and SOS1. Part of a complex containing GRB2 and CBL. Identified in a complex containing FGFR4, NCAM1, CDH2, PLCG1, FRS2, SRC, SHC1, GAP43 and CTTN. Binds RET (By similarity). Binds ALK, FGFR1, CKS2, MAPK1/ERK2, MAPK3/ERK1 and SRC. The tyrosine-phosphorylated protein binds the SH2 domains of GRB2 and PTPN11. Interacts with NTRK1, NTRK2 and NTRK3 (phosphorylated upon ligand-binding). Subcellular Location: Endomembrane system. Note=Cytoplasmic, membrane-bound. Tissue Specificity: Highly expressed in heart, brain, spleen, lung, liver, skeletal muscle, kidney and testis. Post-translational modifications: Phosphorylated by ULK2 in vitro (By similarity). Phosphorylated on tyrosine residues upon stimulation by NGF or FGF2. Phosphorylated on tyrosine residues by activated ALK and FGFR1. Phosphorylated on tyrosine residues upon activation of FGFR2 and FGFR3. Phosphorylated on threonine residues by MAP kinases; this inhibits tyrosine phosphorylation, and thereby down-regulates FRS2-mediated activation of MAP kinases. Ubiquitinated when tyrosine phosphorylated and in a complex with GRB2. The unphosphorylated form is not subject to ubiquitination (By similarity). Similarity: Contains 1 IRS-type PTB domain. Database links: Entrez Gene: 10818 Human Entrez Gene: 327826 Mouse Omim: 607743 Human SwissProt: Q8WU20 Human SwissProt: Q8C180 Mouse Unigene: 593446 Human Unigene: 135965 Mouse Unigene: 22182 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
